Featured Research

from universities, journals, and other organizations

Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends

Date:
February 7, 2013
Source:
Cell Press
Summary:
Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on Feb. 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.
Credit: Cell Reports, Blagoev et al.

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

Related Articles


"We were able to demonstrate that this applied across all patients and that those who had the greatest benefit from the drug while it was administered retained this benefit," says senior author Dr. Tito Fojo, of the National Cancer Institute at the National Institutes of Health.

Sunitinib, which is approved around the world for the treatment of several different cancers, works by targeting proteins on the blood vessels that feed tumors. Animal studies have suggested that treatment with sunitinib may induce changes in tumor vessels or adaptations within tumors themselves that could promote cancer growth and spread.

When Dr. Fojo and his colleagues analyzed more than 10,000 data points from the pivotal randomized phase 3 clinical trial that led to sunitinib's approval, the evidence clearly showed that no matter how long patients took sunitinib, it was not harmful, did not accelerate tumor growth, and did not shorten survival after treatment ended. During treatment, the drug slowed tumor growth and prolonged the patients' survival.

"Last year, I was approached by two patients who had grave concerns about taking sunitinib due to an article conducted in animals. I realized that if clinical data exist that refute basic science, they must be published," recalls Dr. Fojo.

The researchers' findings indicate that sunitinib can benefit patients without altering tumor biology after the drug is stopped. "We hope this can be generalized to similar drugs but recognize that further studies will be needed," says first author Dr. Krastan Blagoev of the National Science Foundation. "Nevertheless, other drugs also approved worldwide for a variety of cancers -- including sorafenib, pazopanib, and axitinib -- are similar to sunitinib, and this will give some reassurances that one need not expect things to get worse after such drugs are discontinued."


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. KrastanB. Blagoev, Julia Wilkerson, WilfredD. Stein, RobertJ. Motzer, SusanE. Bates, A.Tito Fojo. Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma. Cell Reports, 2013; DOI: 10.1016/j.celrep.2013.01.015

Cite This Page:

Cell Press. "Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends." ScienceDaily. ScienceDaily, 7 February 2013. <www.sciencedaily.com/releases/2013/02/130207131513.htm>.
Cell Press. (2013, February 7). Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2013/02/130207131513.htm
Cell Press. "Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends." ScienceDaily. www.sciencedaily.com/releases/2013/02/130207131513.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins